Serum miR‑210‑3p can be used to differentiate between patients with pancreatic ductal adenocarcinoma and chronic pancreatitis
| Autor: | Marek Cybulski, Małgorzata Guz, Agnieszka Mądro, Witold Jeleniewicz, Joanna Kozicka, Jacek Kurzepa |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty endocrine system diseases pancreatic cancer Gastroenterology General Biochemistry Genetics and Molecular Biology chronic pancreatitis 03 medical and health sciences 0302 clinical medicine Internal medicine Pancreatic cancer medicine cancer inflammation of the pancreas General Pharmacology Toxicology and Pharmaceutics serum microRNA Oncogene business.industry General Neuroscience Cancer Articles General Medicine Cell cycle medicine.disease Molecular medicine 030104 developmental biology 030220 oncology & carcinogenesis Pancreatitis Biomarker (medicine) Alkaline phosphatase business diagnostic tool |
| Zdroj: | Biomedical Reports |
| ISSN: | 2049-9442 2049-9434 |
| Popis: | Patients with chronic pancreatitis (CP) are at risk of developing pancreatic ductal adenocarcinoma (PDAC). To the best of our knowledge, there are no suitable non-invasive biomarkers for differentiation between CP and PDAC; however, potential molecular candidates include circulating miRNAs due to ease of extraction, their stability and tissue specificity. Therefore, the aim of the present study was to identify potential serum marker(s) that may be used for differentiating between CP and PDAC. In total, 77 patients were enrolled in the present study; 34 patients with CP, 26 patients with PDAC and a control group of 17 healthy individuals. Expression of miR-10b-5p, miR-106b-5p, miR-210-3p and miR-216a-5p in serum was determined by reverse transcription-quantitative PCR. Serum miRNA expression levels in patients with CP, PDAC and in the control group were compared. Routine biochemical blood parameters were determined and correlation analysis of these parameters with miRNA expression was performed. Expression of miR-210-3p was increased in the sera of patients with PDAC compared with the CP patients (P=0.015) and with the control group (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|